Evommune Overview
Evommune (EVMN) has a ROE of -34.1%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-34.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Evommune (EVMN) currently reports a ROE of -34.1%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Evommune's ROE history and peer comparisons.
Evommune's ROE of -34.1% is lower than the Healthcare sector average of 11.15%. That is roughly 405.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Evommune's current -34.1% should be judged against Healthcare norms (sector average: 11.15%) and against EVMN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -34.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Evommune, and consider following EVMN for alerts when major investors trade the stock.
Evommune is classified in the Healthcare sector. On ROE, it currently shows -34.1% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVMN with unrelated industries.
